Peter Carey
Royal Victoria Infirmary
16 Papers
149 Citations
Peter Carey is an academic researcher from Royal Victoria Infirmary. The author has contributed to research in topics: Total body irradiation & Transplantation. The author has an hindex of 8, co-authored 16 publications. Previous affiliations of Peter Carey include City Hospitals Sunderland NHS Foundation Trust & Newcastle upon Tyne Hospitals NHS Foundation Trust.
Chat about Author
Papers
Ocular complications of bone marrow transplantation.
TL;DR: The data suggest that the incidence of cataract following fractionated TBI is influenced not only by the total dose of radiation but also by its rate of administration (defined by midline tissue dose rate and fractionation schedule), and dry eyes and conjunctival staining may be exacerbated by TBI.
127
Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group.
TL;DR: It is concluded that this method of ABMT results in rapid reengraftment with lack of toxicity and that the conditioning treatment used shows good efficacy against disease, and the results call into question the need for marrow purging in ALL and NHL patients transplanted in first remission.
67
Prevalence of pyruvate kinase deficiency in a northern European population in the north of England
Peter Carey,John Chandler,Alex Hendrick,Michael M. Reid,P. W. G. Saunders,Hazel Tinegate,Penelope R. A. Taylor,Nicholas West +7 more
TL;DR: The prevalence of pyruvate kinase (PK) deficiency in the general white population is estimated to be 51 cases per million white population by gene frequency studies, and this has been found to be low.
43
Severe renal toxicity due to intermediate-dose methotrexate.
TL;DR: Four cases in whom severe renal and mucosal toxicity occurred with intermediate doses (200 mg/m2) of MTX despite folinic acid rescue are presented, and means of avoiding such toxicity are suggested.
39
Myelodysplasic syndromes in children
TL;DR: It is expected that measures will help to reduce further the low mortality from this condition, to help identify more clearly offending drugs and to define more clearly the natural history of this condition.
25